南方财经12月26日电，元隆雅图(002878.SZ)公告称，其募投项目数字营销业务系统建设项目因战略调 整需要，拟终止实施，并将剩余募集资金用于永久性补充流动资金。此次变更主因系公司优化资源配 置、聚焦核心主业发展，具体涉及对原有数字营销系统建设路径的重新评估。 ...

新华医疗（600587）(600587.SH)公告，公司及全资子公司淄博弘新医疗科技有限公司(简称"淄博弘新") 拟在产权交易所预挂牌转让合计持有的新华医疗健康产业(湖北)有限公司(简称"湖北新华医疗")60%股 权及相关债权。该事项旨在聚焦核心主业发展，提升资产运营效率。 ...

智通财经APP讯，新华医疗(600587.SH)公告，公司及全资子公司淄博弘新医疗科技有限公司(简称"淄博 弘新")拟在产权交易所预挂牌转让合计持有的新华医疗健康产业(湖北)有限公司(简称"湖北新华医 疗")60%股权及相关债权。该事项旨在聚焦核心主业发展，提升资产运营效率。 ...

Core Viewpoint - The company plans to divest non-core assets and optimize resource allocation through a series of transactions, focusing on its core business areas to enhance competitiveness and sustainable profitability [2][10]. Group 1: Transaction Overview - The company announced the sale of 100% equity in China Metallurgical Group Real Estate Co., Ltd. and related debts to Wukuang Real Estate Holdings for a total transaction price of 60.676 billion yuan [2][9]. - The transaction includes the sale of 100% equity in several subsidiaries, including Youse Institute, Zhongye Copper Zinc, and others, to China Minmetals [9][10]. - This transaction is classified as a related party transaction and does not constitute a major asset restructuring, requiring approval from the shareholders' meeting [3][9]. Group 2: Purpose and Benefits of the Transaction - The transaction aims to respond to the call for central enterprises to focus on their main responsibilities and optimize resource allocation, marking a key step for the company towards high-quality development [10][11]. - By divesting non-core assets, the company will enhance its business structure, focus on core operations, and improve its core competitiveness and profitability [2][11]. - Post-transaction, the company will concentrate on metallurgical engineering, non-ferrous and mining engineering construction, high-end infrastructure, industrial construction, and emerging industries [10][11]. Group 3: Financial and Operational Implications - The transaction price is set at 60.676 billion yuan, with payment structured in two installments: 50% within 20 days after board approval and the remaining 50% on the delivery date [12]. - The company will utilize the funds from this transaction to support its strategic focus on "one core, two main bodies, and five characteristics" [11][12]. - The divestment is expected to lead to a clearer focus on the company's core business, improving management efficiency and overall operational stability [11].

（1）公司将以79,349.37万元的价格，向厦门正通出售所持有的厦门信达国贸汽车集团股份有限公司 （以下简称"信达国贸汽车"）100%股权。（2）公司全资子公司香港信达诺将以1,992.14万元的价格， 向通达集团出售所持有的国贸汽车（泰国）有限公司（简称"国贸泰国汽车"）90%股权；公司全资子公 司新加坡信达资源将以221.35万元的价格，向升涛发展出售所持有的国贸泰国汽车10%股权。本次交易 完成后，公司不再直接或间接持有信达国贸汽车和国贸泰国汽车股权，信达国贸汽车（含其下属子公 司）和国贸泰国汽车将不再纳入公司合并报表范围。 格隆汇12月5日丨厦门信达(000701.SZ)公布，为回收资源、聚焦核心主业，公司与正通汽车全资子公司 厦门正通汽车集团有限公司（简称"厦门正通"）签署附条件生效的《厦门信达股份有限公司与厦门正通 汽车集团有限公司关于厦门信达国贸汽车集团股份有限公司之股权转让协议》；公司全资子公司香港信 达诺有限公司（简称"香港信达诺"）、信达资源（新加坡）有限公司（简称"新加坡信达资源"）与正通 汽车全资子公司通达集团（中国）有限公司（简称"通达集团"）、升涛发展有限公司（简称"升涛发 展" ...

智通财经APP讯，瑞茂通(600180.SH)公告，公司旗下全资子公司CCSHK拟将其持有的ReunionShipping Assets Management Co., Limited 51%的股权转让给EBRIDGE，转让价格为380.9万美元。该事项旨在进 一步聚焦大宗商品供应链核心主业，公司拟对现有航运业务进行调整优化，以便更好地支撑主营业务。 ...

Core Viewpoint - The company announced a strategic shift by divesting its stake in the subsidiary Lingzhi Yunchuang Technology Co., Ltd. to focus on its core optical business, moving away from the wheel-based medical service and logistics delivery robot sector [2][3]. Group 1: Transaction Details - The transaction consists of two parts: a share transfer and a capital increase, which are interdependent [2]. - The share transfer involves the full subsidiary Lianyi Helite Technology Co., Ltd. selling its stake in Lingzhi Yunchuang, with a transfer price of 14.3 million yuan for a registered capital of 5.6746 million yuan [2]. - Following the capital increase, the registered capital of Lingzhi Yunchuang will rise from 10 million yuan to 12.36 million yuan, with Lianyi Helite's ownership dropping from 100% to 34.9951%, while Wan Ce Zhizao will hold 65.0049% [2]. Group 2: Business Transition - Post-transaction, the company will transfer all non-Lingzhi Yunchuang medical robot-related R&D results, design materials, intellectual property, unfulfilled contracts, and customer relationships to Lingzhi Yunchuang [3]. - Lingzhi Yunchuang, established on May 11, 2024, has a registered capital of 10 million yuan and focuses on the development and sales of intelligent robots, particularly in the medical service and logistics sectors [3]. Group 3: Financial Performance - Lingzhi Yunchuang has reported losses in recent years, with 2024 revenues of 206,200 yuan and a net loss of 3.2282 million yuan, resulting in total assets of 4.466 million yuan and a net asset deficit of 938,200 yuan [3]. - For the period from January to July 2025, Lingzhi Yunchuang generated revenues of 152,480 yuan and a net loss of 623,920 yuan, with total assets of 7.514 million yuan and a net asset deficit of 597,400 yuan as of July 31 [3]. Group 4: Legal and Ownership Status - As of the announcement date, Lingzhi Yunchuang's ownership is clear, with no pledges or restrictions on rights, and it does not involve any major disputes [4].

（文章来源：北京商报） 北京商报讯（记者丁宁）11月28日晚间，新华医疗（600587）发布公告称，公司全资子公司华佗国际发 展有限公司（以下简称"华佗国际"）拟通过公开市场交易方式出售华检医疗控股有限公司（以下简 称"华检医疗"）不超过5%的股份。 新华医疗表示，为聚焦核心主业发展，提升资产运营效率，公司全资子公司华佗国际拟通过公开市场交 易方式（含连续竞价交易、集合竞价交易和大宗交易等某一种或相结合方式）出售华检医疗不超过5% 的股份，华佗国际将基于对华检医疗股票价格的合理判断，根据华检医疗股票价格波动情况及资本市场 整体趋势，逐步实施减持计划，交易价格尚无法确定。 ...

Core Viewpoint - Xinhua Medical (600587.SH) announced a plan to divest up to 5% of its subsidiary Huajian Medical's shares to focus on core business development and improve asset operation efficiency [1] Group 1 - The divestment will be executed through public market transactions, which may include continuous bidding, collective bidding, and block trading [1] - Huajian International will implement the reduction plan gradually based on a reasonable assessment of Huajian Medical's stock price and market trends [1] - The transaction price for the shares to be sold is currently undetermined [1]

新华医疗（600587）(600587.SH)发布公告，为聚焦核心主业发展，提升资产运营效率，公司全资子公 司华佗国际发展有限公司(简称"华佗国际")拟通过公开市场交易方式出售华检医疗控股有限公司(简 称"华检医疗")不超过5%的股份。 ...